Ex-Actavis CEO Paul Bisaro gets top job at Impax to send shares soaring

28 March 2017

Investors were clearly impressed by the appointment of Paul Bisaro as the chief executive of USA-based generics company Impax Laboratories (Nasdaq: IPXL) as the firm’s share value shot up by 37% on Monday to $12.70.

Mr Bisaro succeeds Kevin Buchi, who has served as interim president and chief executive since December 2016.

The newcomer’s 25 years of generic and branded pharmaceutical experience has most recently included being the executive chairman of Ireland-incorporated drugmaker Allergan (NYSE: AGN), president and chief executive of Actavis (formely Watson Pharmaceuticals) and chairman of the board.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK